Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Accounts Payables: 2021-2025

Historic Accounts Payables for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $1.1 million.

  • InMed Pharmaceuticals' Accounts Payables rose 11.72% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 11.72%. This contributed to the annual value of $1.4 million for FY2025, which is 15.10% down from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Accounts Payables stood at $1.1 million, which was down 19.52% from $1.4 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Accounts Payables high stood at $3.4 million for Q4 2021, and its period low was $1.0 million during Q3 2024.
  • Its 3-year average for Accounts Payables is $1.4 million, with a median of $1.4 million in 2024.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Accounts Payables increased by 23.14% in 2022, and later slumped by 55.71% in 2023.
  • InMed Pharmaceuticals' Accounts Payables (Quarterly) stood at $3.4 million in 2021, then plummeted by 41.33% to $2.0 million in 2022, then tumbled by 34.65% to $1.3 million in 2023, then climbed by 6.49% to $1.4 million in 2024, then climbed by 11.72% to $1.1 million in 2025.
  • Its Accounts Payables stands at $1.1 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.